Molecular profile of follicular tumors of the thyroid gland

More than 90 % of newly diagnosed cases of endocrine cancer occur in the thyroid gland. Introduction of fine needle puncture of the thyroid gland, with the classification of cytological material according to the Bethesda system, has become the cornerstone of the diagnosis of malignant neoplasms of the thyroid gland. However, traditionally in this classification there remains a weak link called a follicular tumor (category IV). The detection of a follicular tumor in the cytological material does not allow one to reliably classify the mass as benign or malignant and requires surgical intervention with morphological verification. In recent years, the possibilities of molecular genetic testing have improved markedly. Follicular tumors tend to accumulate mutations, which over time can lead to malignant transformation, but can also be used as a method of timely diagnosis. This review analyzes the literature on the possibilities of molecular genetic testing in assessing the malignant potential of follicular formations of the thyroid gland.

1. Поляков А.П., Мордовский А.В., Никифорович П.А. и др. Клинические наблюдения эффективности терапии метастатического радиойодрефрактерного высокодифференцированного рака щитовидной железы мультикиназными ингибиторами. Эндокринная хирургия 2018;12(2):81–8. Polyakov A.P., Mordovsky A.V., Nikiforovich P.A. et al. Clinical observations of the effectiveness of therapy of metastatic radioiodrefract highly differentiated thyroid cancer with multikinase inhibitors. Ehndokrinnaya khirurgiya = Endocrine Surgery 2018;12(2):81–8. (In Russ.).

2. Dolidze D.D., Shabunin A.V., Mumladze R.B. et al. A Narrative Review of preventive central lymph node dissection in patients with papillary thyroid cancer – a necessity or an excess. Front Oncol 2022;12:906695. DOI: 10.3389/fonc.2022.906695

3. Sung H., Ferlay J., Siegel R.L. et al. Global Cancer Statistics 2020: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. Cancer J Clin 2021;71(3):209–49. DOI: 10.3322/caac.21660

4. De Crea C., Raffaelli M., Sessa L. et al. Actual incidence and clinical behaviour of follicular thyroid carcinoma: an institutional experience. Scientific World Journal 2014:952095. DOI: 10.1155/2014/952095

5. WHO classification of tumours of endocrine organs. 4th edn. Ed. by R.V. Lloyd, R.Y. Osamura, G. Kloppel, J. Rosai. 2017. Available at: https://publications.iarc.fr/Book-And-Report-Series/WhoClassification-Of-Tumours/WHO-Classification-Of-Tumours-OfEndocrine-Organs-2017.

6. Cibas E.S., Ali S.Z. The 2017 Bethesda System for reporting thyroid cytopathology. Thyroid 2017;27(11):1341–6. DOI: 10.1089/ thy.2017.0500

7. McHenry C.R., Phitayakorn R. Follicular adenoma and carcinoma of the thyroid gland. Oncologist 2011;16(5):585–93. DOI: 10.1634/ theoncologist.2010-0405

8. Lamartina L., Grani G., Durante C., Filetti S. Recent advances in managing differentiated thyroid cancer. F1000Res 2018;7:86. DOI: 10.12688/f1000research.12811.1

9. Prete A., Borges de Souza P., Censi S. et al. Update on Fundamental mechanisms of thyroid cancer. Front Endocrinol (Lausanne) 2020;11:102. DOI: 10.3389/fendo.2020.00102

10. Saleh H.A., Jin B., Barnwell J., Alzohaili O. Utility of immunohistochemical markers in differentiating benign from malignant follicular-derived thyroid nodules. Diagn Pathol 2010;5:9. DOI: 10.1186/1746-1596-5-9

11. Nikiforova M.N., Nikiforov Y.E. Molecular diagnostics and predictors in thyroid cancer. Thyroid 2009;19(12):1351–61. DOI: 10.1089/thy.2009.0240

12. Katoh H., Yamashita K., Enomoto T., Watanabe M. Classification and general considerations of thyroid cancer. Ann Clin Pathol 2015;3(1):1045.

13. Nikiforov Y.E., Carty S.E., Chiosea S.I. et al. Highly accurate diagnosis of cancer in thyroid nodules with follicular neoplasm/ suspicious for a follicular neoplasm cytology by ThyroSeq v2 nextgeneration sequencing assay. Cancer 2014;120(23):3627–34. DOI: 10.1002/cncr.29038

14. Williams M.D., Zhang L., Elliott D.D. et al. Differential gene expression profiling of aggressive and nonaggressive follicular carcinomas. Human Pathol 2011;42(9):1213–20. DOI: 10.1016/ j.humpath.2010.12.006

15. Lau L.W., Ghaznavi S., Frolkis A.D. et al. Malignancy risk of hyperfunctioning thyroid nodules compared with non-toxic nodules: systematic review and a meta-analysis. Thyroid Res 2021;25;14(1):3. DOI: 10.1186/s13044-021-00094-1

16. Negro R., Valcavi R., Toulis K.A. Incidental thyroid cancer in toxic and nontoxic goiter: is TSH associated with malignany rate? Results of a meta-analysis. Endocr Pract 2013;19(2):212–8. DOI: 10.4158/ EP12234.OR

17. Zalzal H.G., Chung J., Perini J.A. Remarkable presentation: anaplastic thyroid carcinoma arising from chronic hyperthyroidism. Case Rep Endocrinol 2018:7261264. DOI: 10.1155/2018/7261264

18. Norris J.J., Farci F. Follicular adenoma. In: StatPearls. Treasure Island (FL): StatPearls Publishing, 2022. Available at: https://www. ncbi.nlm.nih.gov/books/NBK559320/.

19. Marques A.R., Espadinha C., Catarino A.L. et al. Expression of PAX8-PPAR gamma 1 rearrangements in both follicular thyroid carcinomas and adenomas. J Clin Endocrinol Metab 2002;87(8):3947–52. DOI: 10.1210/jcem.87.8.8756

20. Fukahori M., Yoshida A., Hayashi H. et al. The associations between RAS mutations and clinical characteristics in follicular thyroid tumors: new insights from a single center and a large patient cohort. Thyroid 2012;22(7):683–9. DOI: 10.1089/thy.2011.0261

21. Tate J.G., Bamford S., Jubb H.C. et al. COSMIC: the catalogue of somatic mutations in cancer. Nucleic Acids Res 2019;47(D1):D941–7. DOI: 10.1093/nar/gky1015

22. Аметов А.С., Дэпюи Т.И., Позднякова Н.В. и др. Генетические маркеры в диагностике рака щитовидной железы. Эндокринология: новости, мнения, обучение 2018;22(1):42–9. Ametov A.S., Depuy T.I., Pozdnyakova N.V. et al. Genetic markers in the diagnosis of thyroid cancer. Ehndokrinologiya: novosti, mneniya, obuchenie = Endocrinology: news, opinions, training 2018;22(1):42–9. (In Russ.).

23. Спирина Л.В., Чижевская С.Ю., Кондакова И.В., Тарасенко Н.В. Роль аутофагии в развитии опухолей щитовидной железы, связь с активацией AKT/m-TOR сигнального пути. Клиническая и экспериментальная тиреоидология 2019;15(3):110–7. Spirina L.V., Chizhevskaya S.Yu., Kondakova I.V., Tarasenko N.V. The role of autophagy in the development of thyroid tumors, the connection with the activation of the AKT/m-TOR signaling pathway. Klinicheskaya i ehksperimental’naya tireoidologiya = Clinical and Experimental Thyroidology 2019;15(3):110–7. (In Russ.).

24. Казубская Т.П., Козлова В.М., Кондратьева Т.Т. и др. Фолликулярно-клеточный (папиллярный и фолликулярный) рак щитовидной железы, генетическая обусловленность и молекулярные маркеры диагностики. Архив патологии 2014;76(5):3–12. Kazubskaya T.P., Kozlova V.M., Kondratieva T.T. et al. Follicularcellular (papillary and follicular) thyroid cancer, genetic conditioning and molecular markers of diagnosis. Arkhiv patologii = Archive of Pathology 2014;76(5):3–12. (In Russ.).

25. Сазонов М.Е., Штандель С.А., Караченцев Ю.И. и др. Молекулярно-генетические маркеры развития фолликулярного рака щитовидной железы. Проблемы эндокринной патологии 2018;2:25–30. Sazonov M.E., Shtandel S.A., Karachentsev Yu.I. et al. Molecular genetic markers of the development of follicular thyroid cancer. Problemy ehndokrinnoi patologii = Problems of endocrine pathology 2018;2:25–30. (In Russ.).

26. Качко В.А., Ванушко В.Э., Платонова Н.М. Прогностическое значение тестирования соматических мутаций и различных методов лечения при высокодифференцированном раке щитовидной железы низкого риска. Эндокринная хирургия 2019;13(2):75–88. Kachko V.A., Vanushko V.E., Platonova N.M. The prognostic value of testing somatic mutations and various treatment methods in highly differentiated low-risk thyroid cancer. Ehndokrinnaya khirurgiya = Endocrine Surgery 2019;13(2):75–88. (In Russ.).

27. Vuong H.G., Kondo T., Oishi N. et al. Genetic alterations of differentiated thyroid carcinoma in iodine-rich and iodinedeficient countries. Cancer Med 2016;5(8):1883–9. DOI: 10.1002/ cam4.781

28. Boos L.A., Dettmer M., Schmitt A. et al. Diagnostic and prognostic implications of the PAX8-PPARγ translocation in thyroid carcinomas-a TMA-based study of 226 cases. Histopathology 2013;63(2):234–41. DOI: 10.1111/his.12150

29. Nikiforova M.N., Biddinger P.W., Caudill C.M. et al. PAX8- PPARgamma rearrangement in thyroid tumors: RT-PCR and immunohistochemical analyses. Am J Surg Pathol 2002;26(8):1016–23. DOI: 10.1097/00000478-200208000-00006

30. Yang J., Gong Y., Yan S. et al. Association between TERT promoter mutations and clinical behaviors in differentiated thyroid carcinoma: a systematic review and meta-analysis. Endocrine 2020;67(1):44–57. DOI: 10.1007/s12020-019-02117-2

31. Wang N., Liu T., Sofiadis A. et al. TERT promoter mutation as an early genetic event activating telomerase in follicular thyroid adenoma (FTA) and atypical FTA. Cancer 2014;120(19):2965–79. DOI: 10.1002/cncr.28800

32. Nicolson N.G., Murtha T.D., Dong W. et al. Comprehensive Genetic analysis of follicular thyroid carcinoma predicts prognosis independent of histology. J Clin Endocrinol Metab 2018;103(7):2640–50. DOI: 10.1210/jc.2018-00277

33. Garcia-Rostan G., Zhao H., Camp R.L. et al. ras mutations are associated with aggressive tumor phenotypes and poor prognosis in thyroid cancer. J Clin Oncol 2003;21(17):3226–35. DOI: 10.1200/JCO.2003.10.130

34. Nilsson M., Fagman H. Development of the thyroid gland. Development 2017;144(12):2123–40. DOI: 10.1242/dev.145615

35. Patel L., Pass I., Coxon P. et al. Tumor suppressor and antiinflammatory actions of PPARgamma agonists are mediated via upregulation of PTEN. Curr Biol 2001;11(10):764–8. DOI: 10.1016/s0960-9822(01)00225-1

36. Jung S.H., Kim M.S., Jung C.K. et al. Mutational burdens and evolutionary ages of thyroid follicular adenoma are comparable to those of follicular carcinoma. Oncotarget 2016;7(43):69638–48. DOI: 10.18632/oncotarget.11922

37. Yoo S.K., Lee S., Kim S.J. et al. Comprehensive analysis of the transcriptional and mutational landscape of follicular and papillary thyroid cancers. PLoS Genet 2016;12(8):e1006239. DOI: 10.1371/ journal.pgen.1006239

38. Kakudo K., Bychkov A., Bai Y. et al. The new 4th edition World Health Organization classification for thyroid tumors, Asian perspectives. Pathol Int 2018;68(12):641–64. DOI: 10.1111/ pin.12737

39. Ganly I., Ricarte Filho J., Eng S. et al. Genomic dissection of Hurthle cell carcinoma reveals a unique class of thyroid malignancy. J Clin Endocrinol Metab 2013;98(5):E962–72. DOI: 10.1210/jc.2012-3539

40. Erickson L.A., Jin L., Goellner J.R. et al. Pathologic features, proliferative activity, and cyclin D1 expression in Hurthle cell neoplasms of the thyroid. Mod Pathol 2000;13(2):186–92. DOI: 10.1038/modpathol.3880034

41. Bai Y., Kakudo K., Jung C.K. Updates in the pathologic classification of thyroid neoplasms: a review of the World Health Organization Classification. Endocrinol Metab (Seoul) 2020;35(4):696–715. DOI: 10.3803/EnM.2020.807